
Kota V Ramana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/719043/publications.pdf Version: 2024-02-01



Κότα V Ραμανία

#	Article	IF	CITATIONS
1	Fortilin interacts with TGF-β1 and prevents TGF-β receptor activation. Communications Biology, 2022, 5, 157.	2.0	5
2	Therapeutic potential of vitamin B ₁ derivative benfotiamine from diabetes to COVID-19. Future Medicinal Chemistry, 2022, 14, 809-826.	1.1	2
3	Aldose reductase regulates doxorubicin-induced immune and inflammatory responses by activating mitochondrial biogenesis. European Journal of Pharmacology, 2021, 895, 173884.	1.7	7
4	Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions. Current Medicinal Chemistry, 2021, 28, 3683-3712.	1.2	12
5	2′-Hydroxyflavanone prevents LPS-induced inflammatory response and cytotoxicity in murine macrophages. Toxicology in Vitro, 2020, 69, 104966.	1.1	8
6	Endotoxin-Induced Uveitis in Rodents. Methods in Molecular Biology, 2019, 1960, 161-168.	0.4	19
7	Lipid Peroxidation Products in Human Health and Disease 2019. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-2.	1.9	29
8	4-Hydroxy-Trans-2-Nonenal in the Regulation of Anti-Oxidative and Pro-Inflammatory Signaling Pathways. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-17.	1.9	27
9	Didymin by suppressing NF-l [®] B activation prevents VEGF-induced angiogenesis in vitro and in vivo. Vascular Pharmacology, 2019, 115, 18-25.	1.0	14
10	Aldose reductase regulates hyperglycemia-induced HUVEC death via SIRT1/AMPK-α1/mTOR pathway. Journal of Molecular Endocrinology, 2019, 63, 11-25.	1.1	60
11	Contribution of Aldose Reductase-Mediated Oxidative Stress Signaling in Inflammatory Lung Diseases. , 2019, , 225-246.		1
12	Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction. Biochemical Pharmacology, 2018, 150, 181-190.	2.0	32
13	Didymin prevents hyperglycemia-induced human umbilical endothelial cells dysfunction and death. Biochemical Pharmacology, 2018, 152, 1-10.	2.0	30
14	Rlip depletion prevents spontaneous neoplasia in TP53 null mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 3918-3923.	3.3	29
15	Aldose Reductase Inhibitor, Fidarestat Prevents High-fat Diet-induced Intestinal Polyps in ApcMin/+ Mice. Current Cancer Drug Targets, 2018, 18, 905-911.	0.8	6
16	Therapeutic Potential of Natural Antioxidants. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-3.	1.9	36
17	Vialinin A, an Edible Mushroom-Derived p-Terphenyl Antioxidant, Prevents VEGF-Induced Neovascularization In Vitro and In Vivo. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-10.	1.9	11
18	Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity. Scientific Reports, 2017, 7, 3182.	1.6	55

#	Article	IF	CITATIONS
19	Aldose reductase inhibitor, fidarestat regulates mitochondrial biogenesis via Nrf2/HO-1/AMPK pathway in colon cancer cells. Cancer Letters, 2017, 411, 57-63.	3.2	40
20	Aldose Reductase Mediates NLRP3 Inflammasome–Initiated Innate Immune Response in Hyperglycemia-Induced Thp1 Monocytes and Male Mice. Endocrinology, 2017, 158, 3661-3675.	1.4	44
21	Regulatory roles of glutathione-S-transferases and 4-hydroxynonenal in stress-mediated signaling and toxicity. Free Radical Biology and Medicine, 2017, 111, 235-243.	1.3	45
22	Aldose Reductase Inhibitor Protects against Hyperglycemic Stress by Activating Nrf2-Dependent Antioxidant Proteins. Journal of Diabetes Research, 2017, 2017, 1-9.	1.0	16
23	Aspalatone Prevents VEGF-Induced Lipid Peroxidation, Migration, Tube Formation, and Dysfunction of Human Aortic Endothelial Cells. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-11.	1.9	13
24	Lipid Peroxidation Products in Human Health and Disease 2016. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-2.	1.9	48
25	Applications of Antioxidants in Ameliorating Drugs and Xenobiotics Toxicity: Mechanistic Approach. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-2.	1.9	11
26	Immune, Inflammatory, and Oxidative Responses in Cardiovascular Complications. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-2.	1.9	4
27	Therapeutic Potential of Natural Pharmacological Agents in the Treatment of Human Diseases. BioMed Research International, 2014, 2014, 1-4.	0.9	39
28	Lipid Peroxidation Products in Human Health and Disease 2014. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-3.	1.9	66
29	Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. Cancer Letters, 2014, 355, 141-147.	3.2	12
30	Aldose reductase regulates acrolein-induced cytotoxicity in human small airway epithelial cells. Free Radical Biology and Medicine, 2013, 65, 15-25.	1.3	26
31	Aldose reductase inhibition suppresses colon cancer cell viability by modulating microRNA-21 mediated programmed cell death 4 (PDCD4) expression. European Journal of Cancer, 2013, 49, 3311-3319.	1.3	36
32	Aldose reductase inhibition enhances TRAIL-induced human colon cancer cell apoptosis through AKT/FOXO3a-dependent upregulation of death receptors. Free Radical Biology and Medicine, 2013, 63, 280-290.	1.3	33
33	Aldose Reductase Inhibition Prevents Colon Cancer Growth by Restoring Phosphatase and Tensin Homolog Through Modulation of miR-21 and FOXO3a. Antioxidants and Redox Signaling, 2013, 18, 1249-1262.	2.5	32
34	Stop Crying over Spilled Milk, Thanks to Recent Reports Which Suggest Novel Therapeutic Options for Existing Aldose reductase Inhibitors. Journal of Biomolecular Research & Therapeutics, 2013, 01, .	0.2	0
35	Aldose Reductase Inhibition Prevents Allergic Airway Remodeling through PI3K/AKT/GSK3β Pathway in Mice. PLoS ONE, 2013, 8, e57442.	1.1	33
36	Lipid Peroxidation Products in Human Health and Disease. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-3.	1.9	56

#	Article	IF	CITATIONS
37	Regulation of NF-B-Induced Inflammatory Signaling by Lipid Peroxidation-Derived Aldehydes. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-11.	1.9	149
38	A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases. Expert Opinion on Investigational Drugs, 2012, 21, 329-339.	1.9	32
39	Focus on Molecules: Lutein. Experimental Eye Research, 2012, 102, 107-108.	1.2	10
40	Prevention of VEGF-induced growth and tube formation in human retinal endothelial cells by aldose reductase inhibition. Journal of Diabetes and Its Complications, 2012, 26, 369-377.	1.2	30
41	Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radical Biology and Medicine, 2012, 52, 182-190.	1.3	49
42	Aldose Reductase Deficiency Protects from Autoimmune- and Endotoxin-Induced Uveitis in Mice. , 2011, 52, 8076.		27
43	Preventive Effects of Ethyl Pyruvate on Endotoxin-Induced Uveitis in Rats. , 2011, 52, 5144.		18
44	Inhibition of aldose reductase prevents endotoxin-induced inflammation by regulating the arachidonic acid pathway in murine macrophages. Free Radical Biology and Medicine, 2011, 51, 1686-1696.	1.3	37
45	Aldose reductase inhibition suppresses airway inflammation. Chemico-Biological Interactions, 2011, 191, 339-345.	1.7	30
46	Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chemico-Biological Interactions, 2011, 191, 330-338.	1.7	144
47	Aldose reductase deficiency protects sugar-induced lens opacification in rats. Chemico-Biological Interactions, 2011, 191, 346-350.	1.7	21
48	Postâ€ŧranslational protein modification by carotenoid cleavage products. BioFactors, 2011, 37, 104-116.	2.6	8
49	Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo. Angiogenesis, 2011, 14, 209-221.	3.7	55
50	Aldose reductase deficiency in mice protects from ragweed pollen extract (RWE)-induced allergic asthma. Respiratory Research, 2011, 12, 145.	1.4	10
51	Aldose Reductase Inhibition Prevents Hypoxia-induced Increase in Hypoxia-inducible Factor-1α (HIF-1α) and Vascular Endothelial Growth Factor (VEGF) by Regulating 26 S Proteasome-mediated Protein Degradation in Human Colon Cancer Cells. Journal of Biological Chemistry, 2011, 286, 24089-24100.	1.6	31
52	Inhibition of aldose reductase prevents colon cancer metastasis. Carcinogenesis, 2011, 32, 1259-1267.	1.3	53
53	Amelioration of Experimental Autoimmune Uveoretinitis by Aldose Reductase Inhibition in Lewis Rats. , 2011, 52, 8033.		13
54	Aldose reductase: new insights for an old enzyme. Biomolecular Concepts, 2011, 2, 103-114.	1.0	144

Kota V Ramana

#	Article	IF	CITATIONS
55	Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications. Recent Patents on Cardiovascular Drug Discovery, 2010, 5, 25-32.	1.5	19
56	Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages. Free Radical Biology and Medicine, 2010, 48, 1423-1434.	1.3	49
57	Prevention of Endotoxin-Induced Uveitis in Rats by Plant Sterol Guggulsterone. , 2010, 51, 5105.		40
58	Aldose Reductase Inhibition Prevents Metaplasia of Airway Epithelial Cells. PLoS ONE, 2010, 5, e14440.	1.1	29
59	Inhibition of Aldose Reductase Prevents Growth Factor–Induced G1-S Phase Transition through the AKT/Phosphoinositide 3-Kinase/E2F-1 Pathway in Human Colon Cancer Cells. Molecular Cancer Therapeutics, 2010, 9, 813-824.	1.9	50
60	Aldose Reductase Regulates Vascular Smooth Muscle Cell Proliferation by Modulating G1/S Phase Transition of Cell Cycle. Endocrinology, 2010, 151, 2140-2150.	1.4	30
61	Aldose reductase: A novel therapeutic target for inflammatory pathologies. International Journal of Biochemistry and Cell Biology, 2010, 42, 17-20.	1.2	156
62	Tumor necrosis factor-alpha converting enzyme: Implications for ocular inflammatory diseases. International Journal of Biochemistry and Cell Biology, 2010, 42, 1076-1079.	1.2	8
63	Aldose reductase inhibition prevents lipopolysaccharide-induced glucose uptake and glucose transporter 3 expression in RAW264.7 macrophages. International Journal of Biochemistry and Cell Biology, 2010, 42, 1039-1045.	1.2	16
64	Inhibition of aldose reductase attenuates endotoxin signals in human non-pigmented ciliary epithelial cells. Experimental Eye Research, 2010, 90, 555-563.	1.2	9
65	Protective effects of magnesium lithospermate B against diabetic atherosclerosis via Nrf2-ARE-NQO1 transcriptional pathway. Atherosclerosis, 2010, 211, 69-76.	0.4	52
66	Measurement and Identification of S-Clutathiolated Proteins. Methods in Enzymology, 2010, 473, 179-197.	0.4	40
67	Aldose reductase inhibition for the treatment of asthma. Expert Review of Clinical Immunology, 2010, 6, 1-4.	1.3	7
68	Inhibition of Aldose Reductase Prevents Experimental Allergic Airway Inflammation in Mice. PLoS ONE, 2009, 4, e6535.	1.1	51
69	Prevention of Posterior Capsular Opacification through Aldose Reductase Inhibition. , 2009, 50, 752.		38
70	Aldose Reductase Inhibition Suppresses the Expression of Th2 Cytokines and Airway Inflammation in Ovalbumin-Induced Asthma in Mice. Journal of Immunology, 2009, 183, 4723-4732.	0.4	43
71	Aldose Reductase Regulates High Glucose-Induced Ectodomain Shedding of Tumor Necrosis Factor (TNF)-α via Protein Kinase C-δand TNF-α Converting Enzyme in Vascular Smooth Muscle Cells. Endocrinology, 2009, 150, 63-74.	1.4	47
72	Genotoxic Effects of Carotenoid Breakdown Products in Human Retinal Pigment Epithelial Cells. Current Eye Research, 2009, 34, 737-747.	0.7	23

#	Article	IF	CITATIONS
73	Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation. Carcinogenesis, 2009, 30, 799-807.	1.3	44
74	Prevention of Endotoxin-Induced Uveitis in Rats by Benfotiamine, a Lipophilic Analogue of Vitamin B1. , 2009, 50, 2276.		49
75	Molecular Cloning and Oxidative Modification of Human Lens ALDH1A1: Implication in Impaired Detoxification of Lipid Aldehydes. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2009, 72, 577-584.	1.1	41
76	Anti-inflammatory effect of aldose reductase inhibition in murine polymicrobial sepsis. Cytokine, 2009, 48, 170-176.	1.4	33
77	Focus on Molecules: Nuclear factor-kappaB. Experimental Eye Research, 2009, 88, 2-3.	1.2	68
78	Cadmium-induced apoptotic death of human retinal pigment epithelial cells is mediated by MAPK pathway. Experimental Eye Research, 2009, 89, 494-502.	1.2	57
79	<scp>l</scp> â€Arginine prevents metabolic effects of high glucose in diabetic mice. FEBS Letters, 2008, 582, 2609-2614.	1.3	27
80	Glutathione level regulates HNE-induced genotoxicity in human erythroleukemia cells. Toxicology and Applied Pharmacology, 2008, 227, 257-264.	1.3	54
81	Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells. Experimental Eye Research, 2008, 86, 70-80.	1.2	72
82	Aldose Reductase-Regulated Tumor Necrosis Factor-α Production Is Essential for High Glucose-Induced Vascular Smooth Muscle Cell Growth. Endocrinology, 2007, 148, 4371-4384.	1.4	44
83	Aldose reductase regulates TNF-α-induced PGE2 production in human colon cancer cells. Cancer Letters, 2007, 252, 299-306.	3.2	59
84	Aldose Reductase Inhibition Prevents Endotoxin-Induced Uveitis in Rats. , 2007, 48, 4634.		79
85	Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages. Free Radical Biology and Medicine, 2007, 42, 1290-1302.	1.3	46
86	Aldose reductase prevents aldehyde toxicity in cultured human lens epithelial cells. Experimental Eye Research, 2006, 83, 408-416.	1.2	24
87	Mediation of aldose reductase in lipopolysaccharide-induced inflammatory signals in mouse peritoneal macrophages. Cytokine, 2006, 36, 115-122.	1.4	65
88	Structure of a glutathione conjugate bound to the active site of aldose reductase. Proteins: Structure, Function and Bioinformatics, 2006, 64, 101-110.	1.5	34
89	Inhibition of Aldose Reductase Prevents Lipopolysaccharide-Induced Inflammatory Response in Human Lens Epithelial Cells. , 2006, 47, 5395.		43
90	Endotoxin-Induced Cardiomyopathy and Systemic Inflammation in Mice Is Prevented by Aldose Reductase Inhibition. Circulation, 2006, 114, 1838-1846.	1.6	97

#	Article	IF	CITATIONS
91	Aldose Reductase Mediates the Lipopolysaccharide-induced Release of Inflammatory Mediators in RAW264.7 Murine Macrophages. Journal of Biological Chemistry, 2006, 281, 33019-33029.	1.6	136
92	Contribution of Aldose Reductase to Diabetic Hyperproliferation of Vascular Smooth Muscle Cells. Diabetes, 2006, 55, 901-910.	0.3	59
93	Aldose Reductase Regulates Growth Factor-Induced Cyclooxygenase-2 Expression and Prostaglandin E2 Production in Human Colon Cancer Cells. Cancer Research, 2006, 66, 9705-9713.	0.4	113
94	Mitogenic Responses of Vascular Smooth Muscle Cells to Lipid Peroxidation-derived Aldehyde 4-Hydroxy-trans-2-nonenal (HNE). Journal of Biological Chemistry, 2006, 281, 17652-17660.	1.6	132
95	Lâ€Arginine Alleviates Hyperglycemiaâ€Induced Vascular Inflammation In Diabetic Mice. FASEB Journal, 2006, 20, A979.	0.2	0
96	Requirement of Aldose Reductase for the Hyperglycemic Activation of Protein Kinase C and Formation of Diacylglycerol in Vascular Smooth Muscle Cells. Diabetes, 2005, 54, 818-829.	0.3	119
97	Regulation of lens aldose reductase activity by nitric oxide. Experimental Eye Research, 2005, 81, 664-672.	1.2	11
98	Role of Aldose Reductase and Oxidative Damage in Diabetes and the Consequent Potential for Therapeutic Options. Endocrine Reviews, 2005, 26, 380-392.	8.9	441
99	Inhibition of aldose reductase attenuates TNFâ€Î±â€induced expression of adhesion molecules in endothelial cells. FASEB Journal, 2004, 18, 1209-1218.	0.2	81
100	Oxidative stress-induced up-regulation of the chloride channel and Na+/Ca2+ exchanger during cataractogenesis in diabetic rats. Journal of Diabetes and Its Complications, 2004, 18, 177-182.	1.2	9
101	Activation of Nulcear Factor-ÂB by Hyperglycemia in Vascular Smooth Muscle Cells Is Regulated by Aldose Reductase. Diabetes, 2004, 53, 2910-2920.	0.3	167
102	Aldose reductase regulates TNF-α-induced cell signaling and apoptosis in vascular endothelial cells. FEBS Letters, 2004, 570, 189-194.	1.3	40
103	Aldose Reductase and the Stress Response. ACS Symposium Series, 2003, , 199-211.	0.5	1
104	Aldose Reductase Regulates Reactive Oxygen Species Mediated-Inflammatory Signals. ACS Symposium Series, 2003, , 213-223.	0.5	0
105	Aldose Reductase Detoxifies Lipid Aldehydes and Their Glutathione Conjugates. ACS Symposium Series, 2003, , 37-48.	0.5	4
106	Role of aldose reductase in TNF-α-induced apoptosis of vascular endothelial cells. Chemico-Biological Interactions, 2003, 143-144, 605-612.	1.7	18
107	Aldose reductase mediates the mitogenic signals of cytokines. Chemico-Biological Interactions, 2003, 143-144, 587-596.	1.7	17
108	Regulation of aldose reductase and the polyol pathway activity by nitric oxide. Chemico-Biological Interactions, 2003, 143-144, 333-340.	1.7	25

#	Article	IF	CITATIONS
109	Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells. FASEB Journal, 2003, 17, 417-425.	0.2	72
110	Aldose reductase mediates cytotoxic signals of hyperglycemia and TNFâ€Î± in human lens epithelial cells. FASEB Journal, 2003, 17, 315-317.	0.2	89
111	Metabolism of Lipid Derived Aldehyde, 4-Hydroxynonenal in Human Lens Epithelial Cells and Rat Lens. , 2003, 44, 2675.		30
112	Aldose Reductase Mediates Mitogenic Signaling in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2002, 277, 32063-32070.	1.6	90
113	RELEVANCE OF ALDO-KETO REDUCTASE FAMILY MEMBERS TO THE PATHOBIOLOGY OF DIABETIC NEPHROPATHY AND RENAL DEVELOPMENT. Renal Failure, 2001, 23, 311-320.	0.8	15
114	Structural and kinetic modifications of aldose reductase by S-nitrosothiols. Biochemical Journal, 2001, 358, 111.	1.7	22
115	Regulation of vascular smooth muscle cell growth by aldose reductase. Chemico-Biological Interactions, 2001, 130-132, 627-636.	1.7	7
116	Characterization of the glutathione binding site of aldose reductase. Chemico-Biological Interactions, 2001, 130-132, 537-548.	1.7	18
117	Involvement of aldose reductase in the metabolism of atherogenic aldehydes. Chemico-Biological Interactions, 2001, 130-132, 563-571.	1.7	45
118	Metabolic regulation of aldose reductase activity by nitric oxide donors. Chemico-Biological Interactions, 2001, 130-132, 573-581.	1.7	8
119	Metabolism of lipid peroxidation product, 4-hydroxynonenal (HNE) in rat erythrocytes: role of aldose reductase. Free Radical Biology and Medicine, 2000, 29, 642-651.	1.3	114
120	Kinetic and Structural Characterization of the Glutathione-binding Site of Aldose Reductase. Journal of Biological Chemistry, 2000, 275, 21587-21595.	1.6	82
121	Selective Recognition of Glutathiolated Aldehydes by Aldose Reductase. Biochemistry, 2000, 39, 12172-12180.	1.2	94
122	Purification and characterization of the hepatic CYP2C and 3A isozymes from phenobarbitone pretreated rhesus monkey. , 1999, 198, 79-88.		5
123	Structural and Kinetic Determinants of Aldehyde Reduction by Aldose Reductaseâ€. Biochemistry, 1999, 38, 42-54.	1.2	173
124	Cardiac Metabolism of Enals. Advances in Experimental Medicine and Biology, 1999, 463, 223-229.	0.8	4
125	Regulation of Aldose Reductase by Aldehydes and Nitric Oxide. Advances in Experimental Medicine and Biology, 1999, 463, 501-507.	0.8	2
126	Kinetic Studies of FR-1, a Growth Factor-Inducible Aldo-Keto Reductaseâ€. Biochemistry, 1998, 37, 12909-12917.	1.2	43

#	Article	IF	CITATIONS
127	Metabolism of the Lipid Peroxidation Product, 4-Hydroxy-trans-2-nonenal, in Isolated Perfused Rat Heart. Journal of Biological Chemistry, 1998, 273, 10893-10900.	1.6	204
128	Modification of Aldose Reductase byS-Nitrosoglutathioneâ€. Biochemistry, 1997, 36, 15801-15809.	1.2	46
129	Contribution of Osmotic Changes to Disintegrative Globulization of Single Cortical Fibers Isolated from Rat Lens. Experimental Eye Research, 1997, 65, 267-275.	1.2	29
130	Active site modification of aldose reductase by nitric oxide donors. BBA - Proteins and Proteomics, 1997, 1341, 217-222.	2.1	21
131	A synthesis of 4-hydroxy-2-trans-nonenal and 4-(3H) 4-hydroxy-2-trans-nonenal. Lipids, 1997, 32, 779-782.	0.7	59
132	Delivery of liposome-sequestered hydrophobic proteins to lysosomes of normal and batten disease cells. , 1997, 47, 341-347.		11
133	A rapid HPLC method for the quantification of GSH and GSSG in ocular lens. Current Eye Research, 1996, 15, 726-732.	0.7	13
134	ATP synthase subunit c storage in the polymorphonucleocytes of late infantile and juvenile batten patients. International Journal of Developmental Neuroscience, 1995, 13, 455-462.	0.7	3
135	Calcium-mediated disintegrative globulization of isolated ocular lens fibers mimics cataractogenesis. Experimental Eye Research, 1995, 61, 303-310.	1.2	24
136	Human placental aldose reductase: role of Cys-298 in substrate and inhibitor binding. BBA - Proteins and Proteomics, 1994, 1205, 207-214.	2.1	31
137	Guanosine 5'-(γ-thio) triphosphate (GTPγS) inhibits phosphorylation of insulin receptor and a novel GTP-binding protein, Gir, from human placenta. FEBS Letters, 1994, 340, 124-128.	1.3	8
138	Identification of the reactive cysteine residue in human placenta aldose reductase. BBA - Proteins and Proteomics, 1993, 1164, 268-272.	2.1	20
139	Carboxymethylation-induced activation of bovine lens aldose reductase. BBA - Proteins and Proteomics, 1992, 1120, 329-336.	2.1	19
140	Aldose reductase: Congenial and injurious profiles of an enigmatic enzyme. Biochemical Medicine and Metabolic Biology, 1992, 48, 91-121.	0.7	143
141	Allopurinol promotes and butylated hydroxy toluene prevents sugar-induced cataractogenesis. Biochemical and Biophysical Research Communications, 1990, 168, 939-943.	1.0	33
142	Glutathione S-transferases of bovine iris and ciliary body: characterization of isoenzymes. Current Eye Research, 1989, 8, 175-184.	0.7	15
143	The effect of oxidants on biomembranes and cellular metabolism. Molecular and Cellular Biochemistry, 1989, 91, 149-157.	1.4	48
144	Functional cysteinyl residues in human placental aldose reductase. Archives of Biochemistry and Biophysics, 1989, 275, 112-121.	1.4	25

#	Article	IF	CITATIONS
145	A novel dinitrophenylglutathione-stimulated ATPase is present in human erythrocyte membranes. FEBS Letters, 1988, 228, 53-56.	1.3	51
146	Microdetermination of aldose and aldehyde reductases from human tissues. Current Eye Research, 1987, 6, 1001-1006.	0.7	5
147	Hyperglycemia-induced activation of human erythrocyte aldose reductase and alterations in kinetic properties. BBA - Proteins and Proteomics, 1986, 870, 302-311.	2.1	48
148	Binding of benzo(a)pyrene to rat lung glutathione S -transferases in vivo. FEBS Letters, 1985, 179, 111-114.	1.3	15
149	Purification and characterization of glutathione S-transferases in human retina. Current Eye Research, 1984, 3, 1273-1280.	0.7	31
150	Lens glutathione depletion of 1-chloro-2,4-dinitrobenzene and oxidative stress. Current Eye Research, 1984, 3, 117-119.	0.7	9
151	Detoxification of xenobiotics by glutathione Sâ€transferases in erythrocytes: the transport of the conjugate of glutathione and 1â€chloroâ€2,4â€dinitrobenzene. British Journal of Haematology, 1983, 55, 419-425.	1.2	61
152	Role of glutathione in the prevention of cataractogenesis in rat lenses. Current Eye Research, 1982, 2, 271-275.	0.7	23
153	Susceptibility of aldehyde and aldose reductases of human tissues to aldose reductase inhibitors. Current Eye Research, 1982, 2, 407-410.	0.7	49
154	Studies in neuronal ceroid lipofuscinosis: Enzymes of liver and brain tissues involved in the defense against oxidative damage. Journal of Neuroscience Research, 1982, 7, 305-311.	1.3	9
155	Studies in neuronal ceroid-lipofuscinosis: Heterogeneous nature of neuronal autofluorescent lipopigments. Journal of Neuroscience Research, 1981, 6, 771-783.	1.3	10
156	Distribution of lysosomal hydrolases in human and bovine ocular tissues. Current Eye Research, 1981, 1, 497-500.	0.7	9
157	Lithium Uptake at Physiological Ion Concentrations in a Human Clonal Neuroblastoma Cell Line. Journal of Neurochemistry, 1980, 34, 1520-1521.	2.1	12
158	Altered α subunits in Tay-Sachs disease. Nature, 1978, 273, 245-246.	13.7	12